glp-1 parkinson's disease does not slow progression in phase 3 study GLP-1a: Going beyond Traditional Use

SKU: 25915281776

Pay in 4 interest-free payments of $5.80 Learn more

Live Spec

GLP 1a: Going beyond Traditional Use Frontiers Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, synuclein, sirtuins, and incretin mimetics in potential therapy Glucagon like peptide 1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Some epidemiologic studies have suggested that the risk of Parkinson's disease is increased among persons with type 2 #Diabetes, with the risk potentially attenuated in those taking glucagon like peptide 1 (GLP 1) receptor agonists. GLP 1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease Molecular Psychiatry

Store: skntheory.com · Domain: skntheory.com